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ABSTRACT
Introduction The COVID-19 pandemic has led to over 100 
million cases worldwide. The UK has had over 4 million 
cases, 400 000 hospital admissions and 100 000 deaths. 
Many patients with COVID-19 suffer long- term symptoms, 
predominantly breathlessness and fatigue whether 
hospitalised or not. Early data suggest potentially severe 
long- term consequence of COVID-19 is development of 
long COVID-19- related interstitial lung disease (LC- ILD).
Methods and analysis The UK Interstitial Lung Disease 
Consortium (UKILD) will undertake longitudinal 
observational studies of patients with suspected ILD 
following COVID-19. The primary objective is to determine 
ILD prevalence at 12 months following infection and 
whether clinically severe infection correlates with severity 
of ILD. Secondary objectives will determine the clinical, 
genetic, epigenetic and biochemical factors that determine 
the trajectory of recovery or progression of ILD. Data will 
be obtained through linkage to the Post- Hospitalisation 
COVID platform study and community studies. Additional 
substudies will conduct deep phenotyping. The Xenon 
MRI investigation of Alveolar dysfunction Substudy will 
conduct longitudinal xenon alveolar gas transfer and 
proton perfusion MRI. The POST COVID-19 interstitial 
lung DiseasE substudy will conduct clinically indicated 
bronchoalveolar lavage with matched whole blood 
sampling. Assessments include exploratory single cell 
RNA and lung microbiomics analysis, gene expression and 
epigenetic assessment.
Ethics and dissemination All contributing studies have 
been granted appropriate ethical approvals. Results 
from this study will be disseminated through peer- 
reviewed journals.
Conclusion This study will ensure the extent and 
consequences of LC- ILD are established and enable 
strategies to mitigate progression of LC- ILD.
INTRODUCTION
The COVID-19 pandemic has led to over 100 
million cases worldwide. In the UK alone, 
there have been over 4 million cases, over 
400 000 hospital admissions and over 100 
000 deaths. A large number of people diag-
nosed with COVID-19 suffer from long- term 
symptoms, predominantly breathlessness and 
fatigue whether or not they were admitted 
to hospital. However, long- term symptoms 
following COVID-19 are more common 
in people who suffered more severe acute 
disease.1–4 There are a number of potential 
causes of long- term breathlessness following 
COVID-19 including thromboembolic 
disease, myocarditis or pericarditis and phys-
ical deconditioning. However, based on early 
data from the COVID-19 pandemic, and from 
other viral infections, a potentially severe 
long- term consequence of COVID-19 is the 
development of long COVID- related intersti-
tial lung disease (LC- ILD).5–7
Interstitial lung disease
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SARS- CoV-2 leads to pronounced inflammation within 
the lung and leads to the development of acute respi-
ratory distress syndrome in a substantial proportion 
of those infected. While data demonstrate that a short 
course of corticosteroids can improve survival in patients 
with hypoxia, there is considerable evidence of long- term 
inflammation even following short- term corticosteroid 
therapy.8 While the inflammatory potential of SARS- CoV-2 
is well described, the fibrogenic potential of SARS- CoV-2 
is currently unknown but is predicted to be substantial 
based on the experience of previous COVID-19 outbreaks 
and emerging data from this pandemic.3 7 9 Meta- analysis 
of initial observations has identified substantial levels of 
LC- ILD with an estimated 27% of CT scanned patients 
having fibrotic changes during hospitalisation, and an 
estimated 33% with fibrotic changes at 6 months, which 
suggests minimal regression over time.7 Similarly, an esti-
mated 21% of patients had lung function impairment 
consistent with restrictive disease and 45% had reduced 
gas transfer, when sampled between 1 and 6 months 
following COVID-19 hospitalisation.7 Risk factors for 
severe COVID-19 include increasing age, male sex and 
comorbidities including hypertension and type 2 diabetes 
mellitus,10 11 which are also associated with progressive 
lung fibrosis.10–12
Pilot data from our consortium13 indicate that novel 
functional imaging methods using 129Xe and 1H MRI are 
sensitive to gas transfer limitation, microstructural airway 
changes and alveolar perfusion deficit in patients with 
both acute and long COVID-19. These methods also have 
some ability to dissect both inflammatory and fibrotic 
pathophysiology and are highly sensitive to disease 
progression in established ILDs.14–18
Given the large number of patients infected with 
SARS- CoV-2, it is vital that the extent of LC- ILD is deter-
mined; its natural history defined particularly whether it 
is time- limited inflammation and reversible, or develops 
into persistent, or even progressive, fibrosis. Deter-
mining the natural history of LC- ILD, and risk factors 
as well as biomarkers related to outcome such as disease 
progression, will enable a precise approach to possible 
treatments such as immunomodulation or antifibrotic 
therapy,6 stratification into clinical trials, prognostica-
tion and appropriate service provision. This will facili-
tate assessment and prioritisation of both conventional 
and novel therapies used in the treatment of COVID-19 
during the acute phase to mitigate the subsequent devel-
opment of LC- ILD. By exploring the long- term implica-
tions of SARS- CoV-2 infection across the full spectrum 
of COVID-19 disease ranging from non- hospitalised 
patients managed in the community with mild symptoms 
to those requiring mechanical ventilation, we will define 
the risk factors for LC- ILD including disease severity, host 
genetic factors and the effects of antiviral and immuno-
modulatory treatment administered during the acute 
phase of the illness.
To address the development of ILD following 
SARS- COV-2 infection, we will determine the prevalence 
and natural history of LC- ILD in the 12 months following 
COVID-19 through linkage to the Post- Hospitalisation 
COVID (PHOSP- COVID) platform study, the REACT 
community study and unique collections such as the 
Xenon MRI investigation of Alveolar dysfunction 
Substudy (XMAS) and POST COVID-19 interstitial 
lung DiseasE (POSTCODE) substudies. The UK Inter-
stitial Lung Disease Consortium (UKILD) will under-
take a longitudinal observational study of patients with 
suspected ILD following COVID-19, to determine the 
clinical, genetic, epigenetic and biochemical factors that 
determine the trajectory of recovery or progression.
METHODS AND ANALYSIS
The UKILD- Long COVID study is a prospective multi-
centre observational cohort study that will be managed 
through the Imperial College National Heart and Lung 
Institute and funded by the UKRI Medical Research 
Council and an NIHR professorship (RGJ). The primary 
study aims to define the prevalence and risk factors 
for LC- ILD using data from 10 000 stratified patients, 
collected from the UK’s national PHOSP for COVID plat-
form study, together with 2000 non- hospitalised patients 
referred for assessment up to 3 months for investigation 
of persistent respiratory symptoms post- COVID-19, such 
as breathlessness and cough (figure 1A). These patients 
will be recruited from Long COVID clinics or commu-
nity Post- COVID-19 clinical trials (REACT Long COVID 
Study19). We will assess the clinical and genetic risk 
factors for post- COVID-19 ILD and radiological classifi-
cation, as well as the trajectory and pathogenic mecha-
nisms of progression following acute COVID with longi-
tudinal analysis of biomarkers and the undertaking of 
two substudies (figure 1B).
1. Up to 80 participants will undergo detailed longitudi-
nal xenon and proton MRI coupled with measures of 
flow- mediated endothelial function in the microvascu-
lature measured by EndoPat.
2. Up to 50 participants will undergo bronchoscopy with 
bronchoalveolar lavage (BAL) for single cell and/or 
bulk RNA sequencing (RNA- seq), with matched flow 
cytometry analysis, as well as microbiome analysis.
Objectives
The primary objective of the study is to determine the 
prevalence of ILD at 12 months following SARS- CoV-2 
infection and whether clinical severity correlates with 
severity of ILD in survivors.
Secondary objectives
1. To further define the LC- ILD population, in particu-
lar, to describe the emerging phenotypes and risk fac-
tors of LC- ILD.
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Figure 1 UK Interstitial Lung Disease (UKILD)- Long COVID study flow. (A) Inclusion and exclusion criteria for UKILD- Long 
COVID study and planned primary analysis. (B) Planned secondary analysis flow and design including UKILD- Long COVID 
substudies. HRCT, High Resolution Computerised Tomography; MDT, Multi- Disciplinary Team; PHOSP- COVID, Post- 
Hospitalisation COVID; POSTCODE, POST COVID-19 interstitial lung DiseasE; COVID ILD, Post COVID ILD; XMAS, Xenon 
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3. To explore pathomechanisms of LC- ILD for candidate 
prognostic and theranostic biomarkers.
The primary end point
The primary end point of the study is as radiologically 
confirmed diagnosis of fibrotic or non- fibrotic ILD in the 
12 months following COVID-19. Substudies will have a 
co- primary end point of change in the radiological extent 
of LC- ILD.
The secondary end points
1. Progressive lung function impairment between 3 
and 12 months, defined as ≥10% relative decline in 
Forced Vital Capacity (FVC), or ≥10% relative decline 
in Diffusion Capacity in Lung of Carbon Monoxide 
(DLco), or increasing radiological extent of LC- ILD 
using image analysis.20
2. Resolution of ILD, as defined by ≥10% relative im-
provement in FVC, DLco or reduction of radiological 
extent.
3. Persistence of ILD in those not meeting definition of 
progression or resolution.
4. Presence of interstitial lung abnormalities on radio-
logical images that do not meet definition of ILD.
5. A comprehensive series of clinical, molecular, MRI and 
biochemical parameters will be assessed as biomarkers.
Selection of participants
The PHOSP- COVID study (ISRCTN10980107) is a 
national consortium that provides a platform to study the 
long- term consequences of COVID hospitalisations.21 An 
expected 10 000 individuals hospitalised by COVID are to 
be included in baseline assessments after testing positive 
on PCR for SARS- C0V-2 and will be recruited through 
the PHOSP platform and will permit a 3- month look 
back period to ensure patient recruitment targets are 
met. The study will also include a further 2000 individ-
uals, with proven COVID, who were not hospitalised but 
presented to Long COVID clinics with persistent respira-
tory symptoms such as breathlessness or cough and are 
referred for cross- sectional imaging (CT) at baseline (3 
months±6 weeks after their first COVID symptoms).22 
A total of up to 12 000 people will be assessed for longi-
tudinal follow- up into the UKILD- Long COVID study. 
Following assessment of patients with Long COVID at 
baseline (~3–6 months postinfection as defined above), 
those with clinical and radiological features suggestive 
of ILD will be included into the UKILD- Long COVID 
study population. Where there are contraindications 
for CT and if clinically indicated, participants will be 
eligible for a research- guided three- dimensional ultra-
short echo time (UTE) proton MRI as a surrogate for CT. 
Where individuals meet criteria for initial study inclusion 
(COVID and clinical indication for CT scanning) but 
have no clinical, radiological or physiological features of 
ILD, they will be invited to enrol as part of the control 
cohort for follow- up.
UKILD-Long COVID inclusion criteria
Patients aged ≥18 years with (a) evidence of SARS- CoV-2 
infection earlier confirmed by microbiology or serology 
and (b) clinical suspicion of Long COVID ILD warranting 
CT or consideration for proton MRI.
POST COvid-19interstitial lung DiseasE (POSTCODE) substudy
Up to 50 participants from various severity strata 
including hospitalised and non- hospitalised patients 
will undergo clinically indicated BAL with matched 
whole blood sampling up to 6 months and then again 
between 12 months±3 months following infection with a 
minimum of 6 months between bronchoscopy and whole 
blood sampling for deep phenotyping. Assessments will 
include exploratory analysis such as single cell and bulk 
RNAseq, flow cytometry analysis, lung microbiomics and 
epigenetic assessment.Participants eligible for secondary 
analyses will be recorded and monitored on a real- time 
study dashboard to support balanced recruitment of 
gender, age and severity of acute infection. Participants 
in secondary analyses will be largely recruited from 
specialist centres for radiological imaging and bronchos-
copy procedures, with other centres referring.
Patients aged ≥18 years with (a) evidence of SARS- CoV-2 
infection confirmed by microbiology or serology and (b) 
clinical suspicion of Long COVID ILD warranting CT or 
consideration for proton MRI, with architectural distor-
tion of the lung defined by abnormal displacement of 
bronchi, vessels, fissures or septa caused by diffuse or 
localised lung disease, particularly interstitial fibrosis.
UKILD - POSTCODE exclusion criteria
 ► Confirmed ILD diagnosis prior to the diagnosis of 
COVID-19.
 ► No CT chest evidence of architectural distortion.
 ► Life- limiting illness within 12 months.
Further exclusion criteria have been selected to support 
distinction of cases and controls during follow- up. Cases 
will have evidence of a radiological abnormality at base-
line scan (up to 6 months) post- COVID-19, with archi-
tectural distortion of the lung defined by abnormal 
displacement of bronchi, vessels, fissures or septa caused 
by diffuse or localised lung disease, particularly intersti-
tial fibrosis,23 while participants included in the control 
population will meet inclusion criteria but have no 
evidence of lung architectural distortion on CT or MRI 
as defined by local PI.24 No evidence of breathlessness 
or respiratory symptoms will act as additional criteria to 
select controls from the same population for comparison 
in longitudinal study. Spirometry and gas transfer do 
not contribute to essential criteria due to potential miss-
ingness regarding safety risks of aerosolisation. Specific 
radiological patterns will not be part of essential criteria 
in order to minimise selection bias and support detailed 
assessment of the potential range of radiological changes 
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implants, claustrophobia and gadolinium contrast agent 
risk) will be exclusion criteria for the xenon MRI substudy.
Study flow/Regimen
Individuals meeting the inclusion criteria for UKILD- 
Long COVID will be followed up using the PHOSP- 
COVID platform, or using specific substudy consent. 
Clinical, molecular, biochemical and patient- reported 
outcome measure (PROM) data will be captured in the 
PHOSP platform using predefined case report forms 
with linkage to retrospective and prospective social and 
healthcare records. Up to 40% of individuals enrolled 
in PHOSP will undergo research- specific biosampling 
and linkages to enhanced clinical records. PHOSP case 
report forms will be completed during the acute COVID 
admission and at 3, 6 and 12 months posthospitalisation. 
Eligible non- hospitalised individuals presenting at Long 
COVID clinics will have physiological tests and biosam-
pling (including whole blood plasma, serum, DNA and 
peripheral blood monocytes) performed alongside a full 
clinical history with clinical evaluation and testing. Longi-
tudinal follow- up will be performed at least 6 months 
following initial assessment up to 15 months postinfec-
tion and will be guided by clinical need. The primary 
analysis will focus on the prevalence of MDT- confirmed 
ILD at any time point up to date of censorship within the 
wider cohort, as well as prevalence of genetic risk factors 
and radiological patterns, assessed overall and according 
to severity strata.
Participants and controls will also be eligible for enrol-
ment into two specific predefined substudies.
The Xenon MRI investigation of Alveolar dysfunction Study
An anticipated 80 participants representing hospital-
ised patients from various severity strata including non- 
hospitalised patients will undergo longitudinal xenon 
alveolar gas transfer and proton perfusion MRI up to 6 
months and then again between 12 months±3 months 
following infection with a minimum of 6 months between 
MRI scans. Pilot data from our consortium indicate that 
novel functional imaging methods using 129Xe and 1H 
MRI are sensitive to gas transfer limitation, microstruc-
tural airway changes and alveolar perfusion deficit in 
patients with both acute and long COVID-19. These 
methods also have some ability to dissect both inflam-
matory and fibrotic pathophysiology and are highly 
sensitive to disease progression in established ILDs.14–18 
Dynamic contrast- enhanced perfusion MRI has sensi-
tivity to regional blood volume (as does Single- Photon 
Emission Computerised Tomography (SPECT)) and has 
added dynamic sensitivity to quantitative regional blood 
flow, pulmonary vascular transit time and endothelial 
leakage all of which are of interest in understanding the 
accompanying endothelial and microvascular patho-
physiology in COVID- ILD. The XMAS study will be 
performed under site- specific protocols already in place 
for scanning patients with acute and chronic COVID-19 
in Sheffield, Nottingham and Oxford ( ClinicalTrials. gov 
NCT04872309).
In a subset of patients, MRI will be coupled with 
Endopat measurements, a Food and Drug Administration- 
approved non- invasive tool which measures changes in 
flow- mediated endothelial function in the microvascula-
ture and is sensitive to changes in systemic vascular func-
tion patients with chronic lung disease,25 26 to explore 
defects in alveolar dysfunction.
Statistical analysis
The prevalence of MDT- confirmed LC- ILD at both early 
(up to 6 months) and then again at late (12 months±3 
months) time points will be assessed within the total 
study population. The prevalence of broader radiolog-
ical abnormalities and phenotypic patterns will also be 
assessed in a descriptive analysis, together with demo-
graphics, haematological and biochemical profiles, 
physiological performance and PROM. Analyses will be 
performed overall and stratified according to hospital-
ised and non- hospitalised, as well as severity of infection 
in hospitalised patients defined above.
All posthospitalised study participants that are part of 
the PHOSP- COVID study will be linked to the centralised 
National COVID-19 Chest Imaging Database (NCCID). 
Imaging data for the relevant NCCID patients will be 
accessible to UKILD- Long COVID study research groups 
after completion and approval of NCCID Data Access 
Requests. Similarly, imaging data from the PHOSP- 
COVID study will be accessible to UKILD- Long COVID 
study research groups after completion and approval 
of PHOSP- COVID Data Access Requests. NCCID will 
provide pre- COVID-19 and acute COVID-19 (inpatient 
chest X- ray (CXR) and CT) imaging, while PHOSP- 
COVID will provide posthospital discharge (CXR and 
CT) imaging for hospitalised patients only. Imaging 
data- flows vary slightly for NCCID and PHOSP- COVID.27 
A link to the NCCID Github page is included in refer-
ences.28 Each CT will be assessed according to the pipe-
line defined in figure 2.
For non- hospitalised patients, the imaging data 
transfer process will replicate that being performed in 
NCCID and PHOSP- COVID. Data will be sent via Image 
Exchange Portal (IEP) from each hospital site to Royal 
Surrey University Hospital NHS Foundation Trust, and 
then to the National Consortium of Intelligent Medical 
Imaging (NCIMI) for storage and distribution.
Putative genetic risk factors for lung fibrosis or severe 
COVID-19 outcomes, as defined by genome- wide asso-
ciation screens,29 30 as well as treatments (eg, antivirals, 
immunomodulation), comorbidities and initial disease 
severity, will be tested for their association with LC- ILD 
and radiological progression, continuously and dichoto-
mised. Risk factors will be assessed in generalised linear 
models, performed overall and according to major radio-
logical patterning phenotypes. Models will be univariable 
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gender, body mass index, smoking history. Directed- 
acyclic graphs will be specified to ensure the minimum 
adjustments are included when estimating associations 
of risk factors. To identify valuable predictors in explor-
atory analysis of a large number of reported or measured 
features, variable selection techniques such as least angle 
regression with bootstrapping,31 and partial least squares 
will be used. A complete case analysis will be performed 
with missingness in data fields reported.
Baseline and longitudinal changes in biomarkers 
reflecting LC- ILD evolution, including circulating factors 
and cell- types from detailed serological and cellular anal-
ysis, will be assessed in multilevel models for repeated 
measures to test associations according to the presence 
or absence of LC- ILD at late time points (12 months±3 
months), and according to progression, resolution or 
persistence of radiological patterns over follow- up time 
points.
A restricted sample of participants with presence of 
architectural distortion confirmed by HRCT will undergo 
deep phenotyping in the two separate substudies XMAS 
and POSTCODE.
XMAS will capture radiological changes in longitu-
dinal 129hyperpolarised xenon MRI (Xe- MR) coupled 
with measures of endothelial dysfunction (EndoPAT) 
between early and late time points. Paired analyses will be 
performed to test the hypothesis that the red blood cell 
to tissue plasma ratio (RBC/TP), or diffusion- weighted 
mean diffusive length scale (LmD), measured by Xe- MR, 
reduces over time in people with LC- ILD; alveolar- 
interstitial- capillary gas transfer (RBC/TP), acinar micro-
structure (LmD) and Dynamic Contrast Enhanced (DCE) 
lung perfusion (mean capillary transit time (MTT), 
pulmonary blood volume (PBV)) have been observed 
to be sensitive to progression in IPF.14–18 Changes in 
Xe- MR indices will be modelled longitudinally and tested 
for correlations with changes in lung function indices, 
FVC and DLco, biomarkers of endothelial- derived vaso-
active/thrombotic hormones as well as systemic vascular 
function. Regional maps of MRI functional parameters 
will be registered to 1H and CT structural imaging and 
calliper. Image analysis from data acquired at the three-
129XE MRI sites will be performed centrally in Sheffield 
with input from UCL on the quantitative CT, Oxford and 
Nottingham (free breathing 1H MRI).
The primary analysis will be the change in radiological 
extent between early and late time points as measured by 
129Xe RBC/TP in paired analysis. Secondary analyses will 
assess changes in 129Xe LmD, and 1H DCE MTT, PBV, as 
well as differences between severity strata with longitu-
dinal modelling data.
POSTCODE will perform multi- omic phenotyping at 
early time points (up to 6 months) and assess potential 
changes later time points (12 months±3 months). Single 
cell RNA- seq and lung microbiome32 analysis will be 
performed on a proportion of the samples obtained from 
clinical BAL up to 6 months following acute infection 
to determine associations with LC- ILD.33 Participants 
will also be offered to consent for a second bronchos-
copy at 12 months±3 months to enable paired analysis. 
Fibrogenic responses will be explored at single cell reso-
lution, and validated by flow cytometry, and the role of 
the microbial community explored. Centres will perform 
procedures and analyses using standardised protocols 
and bioinformatic pipelines.
In addition, this cohort will undergo bulk whole blood 
RNAseq and analysis of epigenetic modifications at 
both the early and late time points to identify longitu-
dinal biological signatures reflecting distinct resolving 
Figure 2 UK Interstitial Lung Disease- Long COVID 
radiological assessment. Classification criteria for 
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phenotypes, compared with persisting or progressive. 
Defining epigenetic signatures will test the hypothesis 
that COVID-19 promotes epigenetic changes that can 
predispose people to lung fibrosis.
The primary aim is to characterise the genetic and 
epigenetic signal from the airways and the microbiome in 
patients with pulmonary fibrosis post- SARS- Cov-2 infec-
tion, while secondary aims will be to elucidate changes in 
the host and microbiome over time following SARS- Cov-2 
infection, as well as differences in the microbiome, 
genetic and epigenetic signatures between patients with 
progressive and non- progressive disease.
Primary analyses will assess the change in the multi- 
omic signals between early and late time points in paired 
analysis according to the separate platforms. Secondary 
analyses will determine biological signatures of resolving 
LC- ILD phenotypes compared with non- resolving in 
baseline and longitudinal models.
Sample size justification
UKILD-Long COVID
Up to 10 000 participants are expected to be recruited 
through the PHOSP- COVID consortium, with a further 
2000 non- hospitalised participants recruited. Post- 
COVID- related breathlessness has been reported to 
affect approximately 40% of people hospitalised with 
severe disease and 10%–20% of people who suffered 
mild COVID. Preliminary analysis from UK and inter-
national studies have described up to 80% of hospital-
ised patients with COVID-19 have the presence of symp-
toms, radiology and lung function changes concordant 
with ILD, depending on the severity of the underlying 
illness. We anticipate approximately 20% (2400/12 000) 
of people recruited into UKILD- Long COVID study will 
have features consistent with ILD for characterisation, 
which will provide sufficient sample size for descriptive 
analysis, evaluation of incidence and prevalence and 
assessment of risk factors.
Genome- wide genotype data are funded through 
GenOMICC and will be available for >4000 participants 
enrolled in PHOSP- COVID; we will conduct genome- wide 
array genotyping in an additional 2000 non- hospitalised 
participants. A common MUC5B polymorphism associ-
ated with (non- COVID) idiopathic pulmonary fibrosis 
has an OR for disease >2. Anticipating approximately 
20% of non- hospitalised participants will have features 
consistent with ILD (400/2000), there will be sufficient 
power to detect associations with ORs >1.65 (minor allele 
frequency 11%) at p<0.0025 with correction for multiple 
testing of a restricted set of 20 independent variants.
An anticipated 1000 LC- ILD participants representing 
balanced strata of initial severity and a minimum 200 
controls will be assessed in longitudinal analysis to iden-
tify biomarkers that describe the natural history. Data 
from prior biomarker studies in IPF estimate a sample 
size of 1000 achieves 90% power to detect a 13 ng/
mL difference in mean MMP7 levels, with a combined 
SD of 0.18 ng/mL in an unbalanced analysis assuming 
85% resolving disease, providing a standardised effect 
of 0.72.34 To minimise confounding in more restricted 
samples sizes, analyses will exclude individuals receiving 
steroids or immunomodulatory therapy at baseline 
assessment.
Xenon MRI investigation of Alveolar dysfunction Substudy
The Xe- MR substudy will be staged. Stage 1 will include 
an interim analysis of the effect and variability between 
12- month (first wave) and 3- month (second wave) 
unpaired scans after recruitment of 20 participants to 
each arm. Only hospitalised participants with radiolog-
ical evidence of architectural distortion will be enrolled 
at stage 1. Stage 2 will use the findings from stage 1 to 
guide strata representation and required sample size for 
a longitudinal analysis of Xe- MR, with an anticipated 
maximum of 80 cases imaged at both early and late time 
points. A sample size of 80 repeat scans will provide 90% 
power to observe effect sizes above 0.40 at alpha 0.05, 
assuming more variability in LC- ILD than observed in 
IPF.
POST COVID-19 interstitial lung DiseasE
The BAL substudy will be performed in up to 50 cases 
representing balanced numbers of hospitalised and 
non- hospitalised participants, and 10 controls. Partici-
pants will be invited to support the strength of these data 
through a follow- up bronchoscopy at 12 (12 months±3 
months) months and repeat measures. Participants who 
undergo bronchoscopy will be consented for whole blood 
sampling to perform longitudinal whole blood RNA- seq 
and epigenetic analyses. Assuming 50 cases, medium- 
sized effects in exploratory biological signatures (Cohen’s 
d=0.5) will be powered at >90% in paired analysis with no 
correction for familywise error, or 70% when controlling 
for 15 independent comparisons. Large effects (Cohen’s 
d=0.8) will be powered at a similar rate when controlling 
for 10 000 comparisons.
Planned interim analyses
As management of Long COVID and post- COVID-19 
pathologies must be adaptive and responsive to novel 
research findings, two planned interim analyses are to be 
conducted to inform the likely number of outcome events 
and the expected power in substudies. The first planned 
interim will be performed after 3- month follow- up of the 
first 1000 participants through PHOSP (10%) to provide 
initial insights into expected radiological patterns and 
to preliminarily describe the potential LC- ILD burden 
for the support of clinical management. The second 
planned interim will be performed following completion 
of 20 12- month Xe- MR from the primary wave of infec-
tion and 20 3- month Xe- MR from secondary waves. An 
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standardised effect to inform recruitment to the longitu-
dinal Xe- MR cohort.
Ethics and dissemination
Study monitoring
 ► Data verification, case report forms (CRFs), study 
co- ordinator.
This study will be conducted in accordance with the 
International Conference on Harmonisation of Good 
Clinical Practice (ICH GCP), the research governance 
framework for health and social care and according to 
the principles as outlined in the Declaration of Helsinki.
All conduct within the study will comply with the prin-
ciples outlined in the Declaration of Helsinki and GCP. A 
study coordinator will ensure compliance with good clin-
ical practice, support collaborative working with indepen-
dent partners (PHOSP consortium, local clinics, industry 
and regulatory bodies), oversee central recruitment 
targets for substudies and support public dissemination.
Electronic CRFs will be used to collect data. Data will be 
submitted electronically to a protected online database. 
Anonymised data may be entered by study staff in order 
to minimise workload on site clinical staff. Patient iden-
tities will be protected and all information held securely. 
Sharing of data with industrial partners will comply with 
General Data Protection Regulations.
Data entered on CRFs and the online database will 
be subject to quality checks to reference source data on 
a regular basis by the study co- ordinator or nominated 
deputy to ensure standardisation and validity of the data 
collected. The study may be monitored by the sponsor or 
other regulatory bodies. For the purposes of audit and 
compliance monitoring, clinical study data will be avail-
able to delegated members of the local study teams, as 
well as to representatives of the sponsor and the study 
co- ordinating team. All trial data, data monitoring and 
audit will be available for inspection as necessitated by 
research ethics committee inspection. Participants will 
be consented to their study data being released for this 
purpose.
Safety reporting
All of the investigations we are performing as part of this 
research are safe and happen in the hospital on a daily 
basis. However, as with all procedures there are risks of 
complications. Patients are at risk of a small amount of 
discomfort from the blood tests required as part of the 
study. Venepuncture will be performed by qualified 
personnel according to best practice techniques to mini-
mise any adverse events (AEs) and where possible, taken 
at the same time as clinically indicated blood samples to 
avoid repeated sampling.
For patients undergoing bronchoscopy, the possible 
risks are detailed in the POSTCODE patient information 
sheet. Common side effects are a transient sore throat and 
hoarse voice and fever like influenza symptoms can occur 
and last for 24–48 hours and usually settle spontaneously 
or with simple analgesia. A rare complication is a chest 
infection, this occurs in <1% of cases.35
For patients undergoing Xenon or proton MRI, 
the possible risks are detailed in the respective patient 
information sheets. Ethics for the XMAS substudy are 
in place at the respective sites of Sheffield, Nottingham 
and Oxford—see accompanying protocols (Sheffield—
Murdoch IRAS ethics ref 265997 19/LO/1115, folio 
adoption reference 42586; Oxford—C- MORE- POST 
IRAS ethics ref 282608 20/NW/0235; Nottingham—
UKILD- Long COVID IRAS ref 19/NE/0330).
All AEs will be recorded and monitored until resolu-
tion or until it has determined that intervention as part 
of the study was not the cause. All AEs, whether expected 
or not, will be recorded. All serious adverse events (SAEs) 
will be reported to the Chief Investigator within 24 hours. 
However, hospitalisations for elective treatment of a pre- 
existing condition do not need reporting as SAEs.
Study oversight
The trial will be overseen by the UKILD consortium 
steering committee. The first planned interim anal-
ysis will be performed after 3- month follow- up of the 
first 1000 hospitalised participants, recruited through 
PHOSP- COVID, to provide initial insights into expected 
radiological patterns and the potential LC- ILD burden. 
The second planned interim will be performed following 
completion of 20 independent 12- month Xe- MR scans 
from the primary wave of infection and 20 independent 
3- month Xe- MR scans from secondary waves.
Patient and public involvement
Action for pulmonary fibrosis charity and patient part-
ners have been involved from the conception of this 
study to inform study design and conduct. They will also 
form part of the ongoing steering committee appraising 
patient facing material and facilitating the dissemination 
of findings to IPF patients and their families.
Dissemination plan
The results from this study will be disseminated via 
regional and national conference platforms, as well as 
being submitted for publication in open access peer- 
reviewed journals in accordance with UK Research 
Council policies. Any publication will include a list of 
investigators, with authors being determined in line with 
the International Committee of Medical Journal Editors 
guidelines, as well as an acknowledgement of roles of the 
study sponsor and funder(s).
CONCLUSION
This longitudinal observational study was designed by the 
UKILD consortium in response to the global SARS- CoV-2 
pandemic to proactively characterise viral- induced 
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ILD centres with integrated academic groups working 
in collaboration with large platforms for COVID-19 
research, including the Coronavirus Clinical Character-
isation Consortium (ISARIC- 4C), PHOSP- COVID plat-
form and REACT Long COVID studies. The study will 
inform the prevalence and burden of LC- ILD to improve 
local referral pathways and guide follow- up where fibrosis 
is suspected, while findings regarding the natural history 
and mechanisms of LC- ILD will support discovery of 
diagnostic, prognostic and theranostic biomarkers to 
improve patient management. Collectively, the objectives 
of this study will ensure that the extent and consequences 
of LC- ILD are established using existing and novel diag-
nostic approaches, informing the design of future clin-
ical trials and strategies to mitigate disease progression.
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